| Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. | bladder, |
| miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. | colorectal, |
| The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. | gastric, |
| This study demonstrates that the sole oncogenic engagement of Met receptor in normal intestinal epithelial cells is sufficient to induce cancerous biological processes that are fundamental to the initiation and progression of colorectal cancers. | colorectal, |
| demethylation of the colon carcinoma cell line HCT116 induces the expression of an illegitimate fusion transcript between an intronic LINE-1 element and the proto-oncogene cMet | colorectal, |
| The Met oncogene and basal-like breast cancer: another culprit to watch out for?. | breast, |
| uncoupled Met down regulation likely functions to amplify the oncogenic signaling of Met in pancreatic tumor cells. | pancreatic, |
| The expression pattern of Von Hippel-Lindau tumor suppressor protein, MET proto-oncogene, and TFE3 transcription factor oncoprotein in renal cell carcinoma in Upper Egypt. | kidney, |
| EGFR and c-Met may interact in a synergistic manner in the oncogenesis and development of non-small cell lung cancer. Expressions were higher in smokers than in nonsmokers. | lung, |
| ovarian carcinomas, the amplification of the MET proto-oncogene is highly selective and commonly occurs in clear-cell adenocarcinoma. | ovarian, |
| Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. | ovarian, |
| A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. | gastric, |
| A splice variant of the c-met proto-oncogene is the predominant population expressed in human gastric mucosa and carcinoma. | gastric, |
| Alteration of the C-met oncogene locus in human head and neck-carcinoma. | HNSC, |
| Activating mutation in MET oncogene in familial colorectal cancer. | colorectal, |
| these results are the first to identify EGFR and MET-receptor-regulated miRNAs representing oncogenic signaling networks in NSCLCs. | lung, |
| Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin s lymphoma. | lymphoma, |
| miR-1 can have a tumor suppressor function in colorectal cancer by downregulating MET oncogene both at RNA and protein level and that reexpression of miR-1 leads to MET-driven reduction of cell proliferation. | colorectal, |
| miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. | colorectal, |
| The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. | osteosarcoma, |